Supernus Pharmaceuticals
SUPN
233 hedge funds and large institutions have $1.15B invested in Supernus Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 66 increasing their positions, 98 reducing their positions, and 28 closing their positions.
91.68% more ownership
Funds ownership: 0% → 91.68% (+92%)
50% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 28
5% more funds holding
Funds holding: 221 → 233 (+12)
1% more capital invested
Capital invested by funds: $1.13B → $1.15B (+$11.3M)
33% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 98
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
39% less call options, than puts
Call options by funds: $1.87M | Put options by funds: $3.05M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$11M |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$10.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.5M |
| 4 |
Morgan Stanley
New York
|
+$3.95M |
| 5 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$3.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.39M |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$9M |
| 3 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$7.96M |
| 4 |
NPIC
Neumeier Poma Investment Counsel
Carmel,
California
|
-$5.46M |
| 5 |
PA
Perceptive Advisors
New York
|
-$5.45M |
SUPN Hedge Fund Activity: Q4 2016 in Review
233 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q4 2016, worth a combined $1.15B — up 1% from $1.13B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new SUPN positions and 28 closed out — a net gain of 14 holders — while 66 added to existing stakes and 98 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $11M. The largest seller was Fidelity Investments, cutting an estimated $9.39M.
- 233 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q4 2016, up from 221 in Q3 2016.
- Funds reported $1.15B of Supernus Pharmaceuticals stock for Q4 2016, up 1% quarter-over-quarter.
- 42 funds opened new Supernus Pharmaceuticals positions in Q4 2016 and 28 closed out, a net change of +14 holders.
- The largest Supernus Pharmaceuticals buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $11M added.
- The largest Supernus Pharmaceuticals seller in Q4 2016 was Fidelity Investments, an estimated $9.39M sold.
Based on aggregated 13F filings for Q4 2016.